JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT03827798

  Condition:   Hidradenitis Suppurativa
  Interventions:   Drug: CFZ533;   Drug: Placebo to CFZ533;   Drug: LYS006;   Drug: Placebo to LYS006
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

  NCT04015518

  Condition:   Palmoplantar Pustulosis (PPP)
  Interventions:   Drug: Spesolimab;   Drug: Placebo
  Sponsor:   Boehringer Ingelheim
  Recruiting
• 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

  NCT03736967

  Condition:   Atopic Dermatitis
  Interventions:   Drug: REGN3500;   Drug: Dupilumab;   Drug: REGN3500 + Dupilumab Combo;   Drug: Placebo
  Sponsors:   Regeneron Pharmaceuticals;   Sanofi
  Recruiting
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

  NCT04003389

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

  NCT04003142

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

  NCT03931785

  Condition:   Irritable Bowel Syndrome With Diarrhea (IBS-D)
  Interventions:   Drug: MD-7246;   Drug: Placebo
  Sponsors:   Ironwood Pharmaceuticals, Inc.;   Allergan Sales, LLC
  Recruiting
• A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT03926169

  Condition:   Hidradenitis Suppurativa
  Interventions:   Drug: Risankizumab;   Drug: Placebo for risankizumab
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Efficacy, Safety and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

  NCT03858634

  Conditions:   Pruritus;   Chronic Idiopathic Urticaria;   Chronic Idiopathic Pruritus;   Lichen Planus;   Lichen Simplex Chronicus;   Plaque Psoriasis
  Interventions:   Drug: KPL-716;   Drug: Placebo
  Sponsor:   Kiniksa Pharmaceuticals, Ltd.
  Recruiting
• Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa

  NCT03852472

  Conditions:   Hidradenitis Suppurativa;   Acne Inversa
  Interventions:   Drug: Avacopan;   Other: Placebo
  Sponsor:   ChemoCentryx
  Recruiting
• Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-angle Glaucoma or Ocular Hypertension

  NCT03850782

  Conditions:   Glaucoma, Open-Angle;   Ocular Hypertension
  Intervention:   Drug: Bimatoprost (SR)
  Sponsor:   Allergan
  Recruiting
• A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis

  NCT03816891

  Conditions:   Prurigo Nodularis;   Pruritis
  Interventions:   Drug: KPL-716;   Drug: Placebo
  Sponsor:   Kiniksa Pharmaceuticals, Ltd.
  Recruiting
• Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

  NCT03720470

  Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Dupilumab;   Drug: Oral Placebo;   Drug: Injectable Placebo
  Sponsor:   Pfizer
  Recruiting
• Effects of Pneumatic Vitreolysis on Macular Hole

  NCT03677869

  Conditions:   Vitreomacular Traction (VMT);   and Full-thickness Macular Holes (MH)
  Intervention:   Device: Intraocular gas (C3F8)
  Sponsors:   Jaeb Center for Health Research;   National Institutes of Health (NIH);   National Eye Institute (NEI)
  Recruiting
• A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

  NCT03673501

  Condition:   Gastrointestinal Stromal Tumors
  Interventions:   Drug: ripretinib;   Drug: Sunitinib
  Sponsor:   Deciphera Pharmaceuticals LLC
  Recruiting
• Effects of Pneumatic Vitreolysis on Vitreomacular Traction

  NCT03647267

  Condition:   Vitreomacular Traction
  Interventions:   Device: Pneumatic Vitreolysis (C3F8 injection);   Other: Observation
  Sponsors:   Jaeb Center for Health Research;   National Institutes of Health (NIH);   National Eye Institute (NEI)
  Recruiting
• A Study Investigating the Efficacy, Safety, and PK Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe AD

  NCT03533751

  Condition:   Atopic Dermatitis
  Interventions:   Biological: etokimab (ANB020);   Drug: Placebo
  Sponsor:   AnaptysBio, Inc.
  Recruiting
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT03435081

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Baricitinib;   Drug: Placebo
  Sponsors:   Eli Lilly and Company;   Incyte Corporation
  Recruiting
• DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

  NCT03321513

  Condition:   Diabetic Macular Edema
  Interventions:   Drug: intravitreous aflibercept;   Drug: Bevacizumab + Deferred Aflibercept Group
  Sponsor:   Jaeb Center for Health Research
  Recruiting
• ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

  NCT03183128

  Condition:   Clostridium Difficile Infection
  Interventions:   Drug: SER-109;   Drug: Placebo
  Sponsor:   Seres Therapeutics, Inc.
  Recruiting
• A Study of Brentuximab Vedotin in Adults Age 60 and Above With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

  NCT01716806

  Conditions:   Hodgkin Disease;   Peripheral T Cell Lymphoma
  Interventions:   Drug: brentuximab vedotin;   Drug: bendamustine;   Drug: dacarbazine;   Drug: nivolumab
  Sponsors:   Seattle Genetics, Inc.;   Bristol-Myers Squibb
  Recruiting
• A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

  NCT03835481

  Condition:   Psoriasis
  Interventions:   Drug: BI 730357;   Drug: Placebo to match BI 730357
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

  NCT03987620

  Condition:   Candida Vulvovaginitis
  Interventions:   Drug: Ibrexafungerp;   Drug: Placebo
  Sponsors:   Scynexis, Inc.;   PPD
  Recruiting
• Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

  NCT03903822

  Condition:   Atopic Dermatitis
  Interventions:   Drug: PF-06700841;   Drug: Vehicle (Placebo)
  Sponsor:   Pfizer
  Recruiting
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting